The clinical presentation and treatment outcomes of ocular tuberculosis: a 5-year experience in an endemic area
Purpose To report the clinical presentations of ocular tuberculosis infection (OTB) and the treatment regimen and outcome in an endemic area. Methods This is a retrospective case series of patients with presumed OTB treated in a tertiary teaching hospital in Hong Kong in 2014–2019. Results Among the nineteen patients recruited, the most common clinical presentation of OTB was retinal vasculitis (42.1%), followed by scleritis, intermediate uveitis, and choroidal tuberculoma (15.8% respectively). 94.7% and 94.4% of the subjects were treated with ATT and steroid, respectively, and 31.6% were put on systemic immunosuppressant prior to the initiation of ATT. Apart from those suffering from intermediate uveitis, most demonstrated good clinical response within 8 weeks of ATT initiation. Conclusion Ocular involvement of TB has been increasingly recognized, especially in endemic regions like Hong Kong. High index of suspicion is recommended for OTB in typical clinical phenotypes or recurrent/resistant ocular inflammation unresponsive to conventional therapy. TB retinal vasculitis was the most common presentation of OTB in this study and OTB generally requires treatment with either regional or systemic steroid together with ATT..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
International ophthalmology - 41(2021), 9 vom: 26. Mai, Seite 3199-3209 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tsui, Jolly [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Anti-tuberculosis treatment |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2021 |
|---|
| doi: |
10.1007/s10792-021-01886-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR044833253 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR044833253 | ||
| 003 | DE-627 | ||
| 005 | 20230519195923.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210815s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10792-021-01886-y |2 doi | |
| 035 | |a (DE-627)SPR044833253 | ||
| 035 | |a (SPR)s10792-021-01886-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tsui, Jolly |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The clinical presentation and treatment outcomes of ocular tuberculosis: a 5-year experience in an endemic area |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2021 | ||
| 520 | |a Purpose To report the clinical presentations of ocular tuberculosis infection (OTB) and the treatment regimen and outcome in an endemic area. Methods This is a retrospective case series of patients with presumed OTB treated in a tertiary teaching hospital in Hong Kong in 2014–2019. Results Among the nineteen patients recruited, the most common clinical presentation of OTB was retinal vasculitis (42.1%), followed by scleritis, intermediate uveitis, and choroidal tuberculoma (15.8% respectively). 94.7% and 94.4% of the subjects were treated with ATT and steroid, respectively, and 31.6% were put on systemic immunosuppressant prior to the initiation of ATT. Apart from those suffering from intermediate uveitis, most demonstrated good clinical response within 8 weeks of ATT initiation. Conclusion Ocular involvement of TB has been increasingly recognized, especially in endemic regions like Hong Kong. High index of suspicion is recommended for OTB in typical clinical phenotypes or recurrent/resistant ocular inflammation unresponsive to conventional therapy. TB retinal vasculitis was the most common presentation of OTB in this study and OTB generally requires treatment with either regional or systemic steroid together with ATT. | ||
| 650 | 4 | |a Ocular tuberculosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Retinal vasculitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Scleritis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Intermediate uveitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Choroidal tuberculoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anti-tuberculosis treatment |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ho, Mary |4 aut | |
| 700 | 1 | |a Lui, Grace |4 aut | |
| 700 | 1 | |a Li, Timothy |4 aut | |
| 700 | 1 | |a Chen, Lijia |4 aut | |
| 700 | 1 | |a Iu, Lawrence |4 aut | |
| 700 | 1 | |a Brelen, Marten |4 aut | |
| 700 | 1 | |a Young, Alvin L. |0 (orcid)0000-0002-4365-3218 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International ophthalmology |d Dordrecht : Springer Science + Business Media B.V., 1978 |g 41(2021), 9 vom: 26. Mai, Seite 3199-3209 |w (DE-627)SPR013244205 |w (DE-600)2009810-8 |x 1573-2630 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:9 |g day:26 |g month:05 |g pages:3199-3209 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10792-021-01886-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 9 |b 26 |c 05 |h 3199-3209 | ||